Can a drug combo or therapy dogs ease PTSD?

NCT ID NCT07771530

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial tests two promising approaches for post-traumatic stress disorder (PTSD): a new combination of two existing drugs (reboxetine and methylphenidate) and dog-assisted therapy. Researchers will compare these against a placebo and occupational therapy in 160 adults with PTSD. The goal is to see which approach better reduces PTSD symptoms and to identify who might benefit most from each treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of reboxetine and methylphenidate (Ritalin), compared with dog-assisted therapy, placebo, and occupational therapy.
What this could lead to
If successful, this could offer a new, more effective treatment option for PTSD, potentially combining medication with therapy to improve symptoms and quality of life.
What could go wrong
This is an early-stage trial, so the drug combination may not prove more effective than existing treatments, and both drugs carry potential side effects. Dog-assisted therapy may also not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTTRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Haifa

    RECRUITING

    Haifa, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.